Key takeaways
- Resistant starch is a family of starch fractions that escape digestion in the small intestine; source and processing matter
- Raw potato starch, high-amylose maize starch, cooled rice and chemically modified starch are not interchangeable interventions
- The studies reviewed here do not establish a dependable general supplement benefit for constipation, IBS or everyday diarrhea; trial design and financial relationships limit interpretation
- Microbiome, butyrate, glucose and weight measurements answer different questions from relief of gut symptoms
- A hospital diarrhea trial and a Lynch-syndrome cancer trial address narrow clinical settings; neither establishes everyday self-treatment
Resistant starch is a family of preparations, rather than one interchangeable treatment. The studies reviewed here do not establish a universal powder or dose for gut symptoms. Constipation and IBS trials have small arms, null comparisons or important design limits; the hospital rehydration result and secondary Lynch-syndrome cancer finding apply to specific clinical settings. A controlled-feeding weight study found a short-term difference, with weight regained during washout. Microbial changes do not themselves establish relief, and commercial support or unreported product-payment terms remain separate limitations (constipation trial; IBS trial; hospital diarrhea trial; CAPP2; weight study).
Contents
Evidence summary · What it is · Forms and grades · How it works · Hype versus evidence · Benefits by claim · What works · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Funding · Regulation · FAQs · Sources
Evidence summary
“Excluded” means excluded from the independent benefit verdict. It does not mean fabricated, useless or automatically methodologically poor. Mixed public and commercial support remains commercially supported. Unresolved procurement remains unresolved.
| Claim | Evidence | Primary source | Funding or conflict | Independent strength |
|---|---|---|---|---|
| Relieves chronic constipation | RS3 blend trial with 98 enrolled; no significant between-group stool/symptom differences | Luk-In 2024 | Thai public innovation grant; procurement unresolved | Insufficient |
| Relieves functional constipation | 34-person before/after intervention; no randomized concurrent starch-free comparison | Rong Li 2026 | Public grants; two Shanghai Jahwa-affiliated coauthors; starch procurement unresolved | Insufficient |
| Normalizes stool consistency | Randomized potato-starch trial in generally healthy adults | Bush 2023 | MSP-funded; commercial author | Excluded |
| Improves bowel symptoms through particular microbes | Same-cohort exploratory correlations; mean symptom scores did not improve | Bush and Alfa 2024 | MSP funding, employee/consultant authors and related patents | Excluded from independent verdict; no causal symptom proof |
| Treats IBS | Small RS4 arm: symptom and quality-of-life changes not superior to placebo | van den Belt 2025 | Dutch public-private funding including ingredient companies | Insufficient clinical result; commercially cofunded |
| Adds fiber during a low-FODMAP diet | Blend pilot; IBS symptom outcomes null and anxiety signal fails multiplicity adjustment | Yan 2026 | University partly funded study and owns product intellectual property | Maker-linked blend; exploratory findings |
| Shortens acute infectious diarrhea | Hospital rehydration formulation trial | Ramakrishna 2008 | Wellcome grant; starch purchase versus donation unresolved | Narrow, provisional evidence; not everyday self-treatment |
| Produces lasting weight loss | Short controlled-feeding crossover difference; regain during washout | Huating Li 2024 | Public funding; Ingredion provided starches, payment terms unstated | Durability and procurement unresolved |
| Prevents cancer | Primary colorectal result null; secondary other Lynch-cancer signal | Mathers 2022 | Public/charitable funding plus commercial support | Lynch-specific; not general cancer prevention |
What it is
Most dietary starch is broken down and absorbed before reaching the colon. Resistant starch (RS) is the portion that escapes digestion and absorption in the small intestine. It can occur within foods or be concentrated and processed as an ingredient. High-amylose maize starch contains digestible and resistant fractions, so powder weight is not automatically the RS dose (EFSA definitions). The FDA letter cited here concerns a specified high-amylose maize ingredient in supervised rehydration use, rather than approval of every retail powder (GRN 615 response).
An ingredient name should therefore identify the plant source, preparation and measured resistant fraction. “Starch,” “dietary fiber” and “resistant starch” describe overlapping quantities, not three interchangeable label terms. Potato starch is also different from potato flour, which contains other potato components.
A trial of a specific isolated starch cannot directly establish the effects of a meal containing cooked legumes, whole grains or potatoes. Conversely, an association involving an overall high-fiber diet cannot tell us which isolated powder caused the apparent benefit. The food matrix and the foods displaced by the intervention are part of the question.
Forms and grades
The numbered types describe why starch resists digestion. They are not a ranking from least to most effective.
| Type | Why it resists digestion | Examples or preparation | Important qualification |
|---|---|---|---|
| RS1 | Physically enclosed within food structures | Intact or partly intact grains, seeds and pulses | Milling, chewing and processing can alter accessibility |
| RS2 | Resistant native starch granules | Unheated potato or green-banana starch; high-amylose maize | Heating and water can change resistance; different RS2 sources need not behave alike |
| RS3 | Reassociated starch after gelatinization and cooling | Some cooked-and-cooled rice, pasta or potatoes; manufactured retrograded starch | Food, temperature, time and later preparation determine the final amount |
| RS4 | Chemical modification limits enzymatic digestion | Certain cross-linked or substituted starch ingredients | A broad technical category, not one uniform product |
| RS5 | Starch forms complexes with lipids | Amylose-lipid complexes produced under specific conditions | Much of the evidence is physicochemical; it has no established superiority for gut symptoms |
The UK government's carbohydrate report defines RS1–RS4. Laboratory work illustrates RS5 formation and why cooking and retrogradation change digestibility. These sources establish terminology and physical behavior, not human treatment effects. SACN report, definitions, Guo and colleagues 2021 laboratory abstract
A food may contain more than one fraction. Reheating does not have a universal, all-or-nothing effect across recipes. Neither a spoonful of household starch nor a serving of cooled rice can be assumed to reproduce the measured intervention in a published trial.
For product comparison, ask for grams of resistant starch per serving, the analytical method, preparation instructions, other ingredients and allergen information. A total-fiber figure can include other fibers. A trade name or “clinical grade” label alone does not verify equivalence to a research preparation.
How it works
Starch reaching the colon becomes available to microbes rather than being fully absorbed as glucose in the small intestine. Fermentation can generate short-chain fatty acids and other products. That is a plausible route to altered stool characteristics and host metabolism. It is also a reason fermentation-related symptoms deserve attention. FDA ingredient assessment, NIDDK gas guidance
Several measurements sit along this proposed pathway:
- How much of the starch actually escapes digestion
- Which microbes use it under the participant's existing diet
- Which metabolites are produced, absorbed or excreted
- Whether pain, stool passage, daily functioning or disease outcomes improve
Demonstrating an earlier step does not establish the later ones. Fecal butyrate is the amount remaining in the collected sample, affected by production and absorption; it is not a direct measure of tissue delivery (original trial discussion). A bacterial change is not by itself proof of better symptoms. The Thai trial changed microbial measures without a significant stool or constipation-score advantage, and the potato-starch secondary analysis found correlations without an improvement in mean symptom scores (Thai trial; secondary analysis). These studies do not validate a universal stool-microbiome treatment target.
Hype versus evidence
A prebiotic label is not a diagnosis-specific treatment claim. An ingredient may change microbial measurements while leaving the symptoms that brought someone to treatment unchanged.
More papers need not mean more trials. The 2024 potato-starch symptom paper reanalyzed 70 per-protocol participants from the earlier cohort. It found exploratory taxon–symptom correlations, although mean symptom scores did not significantly improve. Correlations cannot identify a causal treatment mechanism, and repeat publications cannot count as separate confirmation. MSP funded the work; the authors disclosed an employee, a consultant and related sister-company patents (Bush and Alfa 2024).
“University funded” does not settle financial independence. Edith Cowan University partly funded the ur gut study and owns the tested product’s trademark and patent application. Those disclosures are relevant alongside its small sample, blend design and exploratory findings (original funding and IP disclosures).
Replacing digestible starch differs from adding a supplement. EFSA found a reduced post-meal glucose response when RS replaced digestible starch in foods; the effect generally was not observed when available carbohydrate stayed the same. This is not proof that adding powder to an unchanged diet treats diabetes or bowel symptoms (original EFSA assessment).
Cooling food to change its starch content must preserve food safety. The FSA advises cooling cooked rice quickly, ideally within an hour, refrigerating it for no more than one day and reheating it only once. A speculative RS gain does not replace those handling precautions (official food-safety guidance).
Benefits by claim
Constipation and stool consistency Insufficient
A Thai trial randomized 98 adults; 87 completed it. It used 9 g/day of HarunaPlus, a mixed-source preparation, for 12 weeks, with soy protein and isomalt in the comparator. Despite its abstract’s positive framing, the Results and clinical figure report no significant between-group stool-frequency, consistency or constipation-score advantage. The National Innovation Agency funded the study, and the authors declared no conflicts; the product’s resistant fraction, purchase/donation terms and other manufacturer support remain unresolved (Luk-In 2024 original results). The registry was first posted after the primary study period (registration dates).
A 2026-volume paper studied 34 patients receiving two 10 g HI-MAIZE 260 sachets daily for 14 days. The human intervention lacked a randomized concurrent starch-free comparison. A separate observational patient–healthy cohort does not supply that control; before/after scores and responder analyses cannot separate treatment from expectation or symptom fluctuation. Public grants and a no-competing-interests declaration appear alongside two Shanghai Jahwa United Co. Ltd.-affiliated coauthors who contributed to formal analysis. Product-payment terms and the actual resistant fraction remain unknown (Rong Li original methods, Figure 6 and disclosures).
A Solnul trial randomized 75 generally healthy adults; 72 entered the full analysis and 70 the per-protocol analysis. It reported selected stool-consistency and bacterial changes, particularly at the lower dose. The bacterial comparisons involved outlier exclusions, and stool tests pooled seven bowel movements per participant rather than measuring independent patient-level constipation responses. IBS and important gastrointestinal disorders were excluded. MSP funded research and publication; disclosed relationships include an employee, prior consultants, a contracted research organization and related sister-company patents (Bush 2023 original methods and tables). The registration was retrospective (registry dates and outcomes).
A two-week Japanese high-amylose wheat-food trial randomized 76 constipation-prone healthy adults and found no significant advantage on its primary bowel-frequency outcome. A secondary fecal-metabolite finding and post-hoc low-fiber subgroup do not establish symptom relief, especially without adjustment for multiple testing. The foods also differed in other nutrients and fiber. Nisshin Seifun Group funded and supplied foods, and six coauthors were employees (Iwata 2026 original tables and declarations).
These studies leave an important practical gap: independently financed trials using verified procurement, meaningful constipation outcomes and adequate follow-up. A stool-frequency change should also be weighed against straining, pain, completeness of evacuation and rescue-treatment use.
IBS symptoms Insufficient
The Dutch trial used 20 g/day of NOVELOSE 3490 RS4 ingredient over four weeks, including a five-day half-dose run-in. Its RS arm had 14 participants in intention-to-treat analysis and 12 in clinical per-protocol analysis; the sample calculation concerned a bacterial endpoint. IBS severity, quality of life, stool frequency and consistency did not outperform placebo. Public-private cofunding included nine companies. These small arms do not exclude every possible RS effect, but they do not establish symptom efficacy (van den Belt 2025).
The 2026 ur gut pilot had 30 consented participants and 26 completers, analyzed per protocol. During a low-FODMAP diet, a high-amylose starch–psyllium blend was compared with maize lacking RS plus the same psyllium. IBS severity and bowel outcomes did not improve relative to control. The GI-specific anxiety and sexual quality-of-life signals did not survive false-discovery-rate adjustment; microbial findings remain exploratory. Edith Cowan University partly funded the study and owns its trademark and patent application. This is neither confirmed anxiety treatment nor independent evidence for starch alone (Yan original Results, analysis and IP disclosure).
A 2022 potato–banana–apple-fiber blend study randomized 40 participants. Its comparator initially tested low in RS, but returned material contained about 52.6% RS versus 55.7% in the blend; it was not an RS-free placebo. Dose/adherence associations and blend effects cannot isolate resistant starch or establish a dependable IBS treatment. Metagenics funded and supplied the blend and helped design and initially write the study; company-linked authors and Amway-provided smart caps were disclosed (Hanes original methods, results and disclosures).
Acute diarrhea — A narrow clinical signal with unresolved independence
An Indian hospital trial randomized 50 men with severe watery diarrhea; 22 had cultured cholera. Both groups received standard care including initial intravenous rehydration and doxycycline. Replacing glucose with high-amylose maize starch in a specified electrolyte solution shortened median time to formed stool from 42 to 19 hours. The total-stool-weight comparison was nonsignificant after multiplicity adjustment. Participants could recognize the solutions, although outcome assessment was blinded. Wellcome funded the study; National Starch’s ingredient was identified but payment terms were unstated (Ramakrishna original methods and results).
This finding concerns a specially prepared electrolyte solution and acute dehydrating illness. It does not establish that kitchen starch treats IBS diarrhea or that adding starch to a standard rehydration sachet is safe. Do not alter an oral-rehydration recipe on this basis.
Microbiome and butyrate claims Insufficient for a clinical verdict
Changes in microbial composition are research findings, not an automatic benefit grade. The practical question is whether a person feels or functions better, or has fewer clinically important events. Trials should prespecify those outcomes and show an advantage over an appropriate comparison.
Commercial support does not invalidate a microbiome measurement. It does remove that study from this review's independent outcome basis. Publicly funded reviews cannot restore the independence of commercially funded underlying experiments.
Weight and metabolic markers — Separate from gut symptom relief
In 37 adults with excess weight, an eight-week controlled-feeding crossover trial found a body-weight difference of −2.81 kg between RS and the energy-matched comparison (95% CI −3.55 to −2.07). Insulin sensitivity also improved, but weight was regained during washout. Participants received 40 g/day of measured RS in 91.2 g powder with controlled meals. Public Chinese, Hong Kong and European/German programs supported the work. Ingredion provided both starches, with purchase versus donation unstated. This short trial does not establish lasting weight loss, diabetes prevention or gut-symptom relief (Huating Li original clinical results and disclosures).
The separate 12-week STARCH prediabetes trial did not improve its primary insulin-sensitivity outcome. A small HbA1c difference partly reflected deterioration in the comparison group and does not establish diabetes prevention. The paper disclosed NIH support plus Ingredion research funding and product gifts for this study. Its metabolic measurements are separate from clinical bowel outcomes (Peterson original results and declarations).
No claim that resistant starch replaces obesity or diabetes treatment follows from these reports. Proposed mechanisms explored in mice remain separate from the human clinical findings.
Cancer prevention — No broad claim justified
CAPP2 randomized 918 people with Lynch syndrome in its starch comparison. Extended follow-up reported:
| Endpoint | Starch group | Placebo group | Hazard ratio with 95% confidence interval |
|---|---|---|---|
| Participants developing colorectal cancer | 52 of 463 | 53 of 455 | 0.92, 0.62–1.34 (original Table 3) |
| Participants developing other Lynch-associated cancers | 27 of 463 | 48 of 455 | 0.54, 0.33–0.86 (original Table 3) |
Colorectal cancer was the primary cancer outcome; other Lynch-associated cancers were secondary. Planned follow-up was ten years, with up to twenty years only in selected England, Wales and Finland cohorts. The primary result was null; the secondary signal was disease-specific. It is not a general-population prevention result. Alongside trial-level commercial support, the disclosures include National Starch/Bayer nonfinancial support and other author relationships outside the submitted work; those roles should not be conflated (Mathers original results and disclosures).
The intervention was an equal blend of Novelose 240 and 330, not ordinary cooled food. The protocol specifies 30 g treatment starch, equivalent to 13.2 g resistant starch. Its factorial design separately tested aspirin; the starch comparison must not inherit benefits from the aspirin arm. National Starch provided product and associated logistics, while Bayer supplied treatment and contributed trial costs. Mixed public and charitable financing does not make this an independent intervention under the stated standard. CAPP2 protocol
For someone with Lynch syndrome, these findings belong in specialist discussion alongside established surveillance and prevention. They do not support replacing screening with a supplement.
What works and what does not
| Proposed use | Verdict under this review's standard | Why |
|---|---|---|
| A universal daily supplement for gut health | Insufficient evidence | Undefined target, heterogeneous products and unresolved or commercial support |
| Chronic constipation treatment | Insufficient evidence | Small or indirect human studies; independent confirmation lacking |
| Global IBS symptom relief | Insufficient evidence | Small commercially linked or mixed-ingredient trials |
| Ordinary diarrhea self-treatment | Insufficient evidence | Hospital rehydration research answers a different question |
| Using microbiome changes to claim disease prevention | Does not establish the claim | A surrogate cannot substitute for the clinical endpoint |
| Weight loss or metabolic disease treatment | Insufficient independent evidence | Commercial support or unresolved procurement limits interpretation; gut benefit cannot be inferred |
| General cancer prevention | Insufficient evidence | CAPP2 was commercially supported and restricted to Lynch syndrome |
| A specific EU food-substitution glucose claim | Authorized within defined conditions | Regulatory status is addressed below; it is not a general gut-treatment verdict |
No broad clinical claim receives “Works” from this audited independent evidence set. That conclusion should change if adequately controlled, independently supported studies establish a reproducible benefit.
Risks and side effects
| Issue | What is known | What remains uncertain |
|---|---|---|
| Gas, bloating and discomfort | The Solnul trial reported possibly related gas and other gut complaints; its narrative and adverse-event table disagree about which dose had more affected participants | Exact dose comparison is unreliable without clarification; Bush 2023, safety section and Table 6 |
| Fermentation symptoms generally | Microbial breakdown of incompletely digested carbohydrate can generate gas; IBS can increase symptom sensitivity | Reliable RS-type-specific adverse-event rates and individual tolerance predictions; NIDDK |
| Nausea | One participant in the ur gut blend group stopped because of nausea | Cannot attribute this to starch rather than the blend, or derive a general risk rate; Yan 2026 |
| Abdominal pain and diarrhea during trials | The Dutch five-arm trial reported four mild-to-moderate events possibly/probably related to interventions or procedures | The pooled report is not an RS-specific count; van den Belt 2025 |
| Ingredient or contaminant exposure | Actual formulation and botanical source matter | A category name does not establish suitability with food allergy or celiac disease |
| Improperly cooled starchy food | Rice requires prompt cooling and appropriate refrigeration; leftover safety remains important | A recipe's claimed resistant-starch gain does not neutralize foodborne hazards; FSA rice guidance |
| Long-term concentrated supplementation | The reviewed studies differ greatly in duration and population | No universal upper safe supplement dose or complete long-term safety profile across RS1–RS5 was established |
A participant's lack of symptoms in a short trial cannot certify safety for people excluded from that trial. Neither a “natural” description nor food-use status supplies the missing clinical data.
Interactions
| Substance or treatment | Reason for attention | Status and practical boundary |
|---|---|---|
| Oral medicines | Formulation, transit and absorption could matter, but the audited trials are not comprehensive pharmacokinetic studies | Clinical magnitude unresolved; no universal medicine-spacing interval established here |
| Insulin and other glucose-lowering treatment | Replacing digestible carbohydrate may alter the meal being treated | This is a dietary-treatment coordination issue, not a proven universal drug interaction; do not change medication using the supplement literature |
| Antibiotics, probiotics and other prebiotic supplements | They can change the context in which an ingredient is being tested | No validated across-product combination or scheduling rule emerges from these studies |
| Laxatives or prescribed bowel regimens | Additional stool changes can complicate evaluation of benefit or intolerance | Do not infer that a supplement permits stopping prescribed treatment |
| Oral rehydration solutions | Clinical starch formulas use specified electrolyte and carbohydrate composition | The hospital trial does not authorize modifying commercial sachets; Ramakrishna 2008 |
These are evidence gaps and precautionary boundaries, not a list of established harmful interactions. Interactions with common prescriptions, minerals, other supplements and repeated high-dose combinations have not been comprehensively characterized here. A pharmacist needs the actual product and medicine list.
Who should avoid self treatment
Seek prompt assessment for constipation accompanied by blood in the stool, persistent abdominal pain, inability to pass gas, vomiting, fever or unintended weight loss. Persistent symptoms also warrant review rather than indefinite supplement escalation. NIDDK warning signs
People with suspected obstruction, significant bowel narrowing, severe motility problems or a prescribed nutrition plan should not improvise concentrated-fiber treatment. Pregnancy, breastfeeding, childhood and serious gastrointestinal disease require population-specific evidence; the adult supplement literature does not settle suitability. These are limits on extrapolation, not claims that all resistant-starch foods are harmful in those groups.
Avoid a preparation that has caused an allergic reaction. A wheat-derived or blended product needs its own allergen and gluten assessment. Acute dehydration and a suspected cancer-related symptom need appropriate care, not a trial of powder.
Dosage and how it was studied
These are research exposures, not prescriptions or recommended starting doses. Grams of an ingredient, resistant starch and total dietary fiber must be kept separate.
| Setting | Reported daily exposure | Duration | Interpretation |
|---|---|---|---|
| Healthy adults, Solnul | 3.5 or 7 g potato-starch ingredient, approximately 2.1 or 4.2 g RS | 4 weeks | Commercially funded; primary report and secondary methods |
| Functional constipation, exploratory intervention | Two 10 g HI-MAIZE 260 sachets | 14 days | Paper calls this RS; exact resistant fraction not independently established; Rong Li |
| Low-FODMAP IBS blend | Escalation to 40 g/day blend; nominal composition implies 14.4 g RS, but reported total intake was 9.5 g/day | 3 weeks, including 11-day escalation | Nominal and reported intake are not reconciled; blend and university IP (Yan original methods and intake results) |
| Controlled feeding, excess weight | 91.2 g study powder providing 40 g RS | 8-week periods | Energy-matched crossover with controlled meals; weight regained in washout, payment terms unresolved (Huating Li) |
| CAPP2 | See the protocol distinction above | About 2 years, with optional extension | Do not convert the powder weight into pure RS; protocol |
| Hospital diarrhea | 50 g high-amylose maize starch per liter of a specified solution | Acute inpatient care | A concentration, not a daily supplement dose; Ramakrishna |
There is no independently established universal dose for “microbiome repair.” The largest studied exposure is not a general safety ceiling. Food preparation and the analytical method can change the measured resistant fraction, making spoon-based equivalence particularly unreliable.
Animal and in vitro evidence
Laboratory digestion experiments are useful for understanding starch structure and why cooking changes it. They cannot show how often people will have comfortable stools or less abdominal pain. The RS5 conference abstract reports university support, but its limited reporting and laboratory design exclude it from human benefit grades. Laboratory abstract
The 2026 constipation paper contains extensive mouse and microbial experiments. Its human intervention is evaluated separately above. Likewise, the 2024 metabolic study's mechanistic experiments in mice do not establish that the same pathway explains a sustained clinical benefit in humans. Rong Li, Huating Li
Animal-only treatment results, fermentation-vessel changes and disease-risk biomarkers are excluded from the human efficacy verdict.
Independent funding tracing
Research funding at a glance
32 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
What qualified and what did not
The audit separates three questions: who paid, who supplied the intervention, and who might profit. “No competing interests” is not enough if a manufacturer funded research, donated products or contributed other in-kind research support. Buying an ingredient at arm’s length is not itself sponsorship, and unstated payment terms remain unknown. Public funding does not erase documented commercial support, and university ownership of a tested product matters.
The Dutch study names nine commercial cofunders: Bioiberica, Roquette, Ingredia, Ingredion, Givaudan France Naturals, Nexira, WeCare Probiotics, Winclove Probiotics and Darling Ingredients Nederland. Chinese scholarship support also appears in its disclosures. Rong Li’s public-grant paper includes two Shanghai Jahwa-affiliated coauthors; its no-conflicts line does not erase that affiliation. Yan’s university owns the tested product’s IP. These are different relationships, not a single academic-independence certificate (Dutch funding statement; Rong Li affiliations and contributions; Yan IP disclosures).
Wellcome's current financial statement says its funds come from an investment portfolio. That model deserves scrutiny, but does not establish that a starch company directed the old diarrhea trial. The unresolved issue remains that study's product procurement. Upstream investments were not comprehensively matched to historical ingredient holdings. Wellcome 2024–25 report announcement
Who benefits commercially
Ingredion sells specialty ingredients and is headquartered in the United States. Corn Products International acquired National Starch in 2010 and later adopted the Ingredion name. This corporate history connects old and current commercial names; it does not retroactively assign today's shareholders responsibility for earlier trial conduct. SEC-filed acquisition announcement, company timeline
Ingredion's 2026 proxy reports BlackRock beneficial ownership of 10.4%, calculated using the 23 March 2026 share count and BlackRock's older reported position. Its Vanguard note describes a reporting realignment, not proof that underlying investment clients sold every share. These are dated disclosed positions, not verified live holdings or evidence of investor control over a particular trial. 2026 proxy, ownership section
MSP Starch Products, based in Carberry, Canada, funded the Solnul work. Manitoba's government announced a CAD 100,000 grant in 2023 to expand the ingredient's market reach. That is documented commercialization support, not evidence that the government independently validated a clinical benefit or financed the earlier trial. Ultimate private owners and current ownership percentages were not resolved. Manitoba grant record
Metagenics, based in California, is backed by US private-investment firm Gryphon Investors, as confirmed in a January 2026 announcement. Gryphon's earlier acquisition announcement named Alticor as the seller. Current exact ownership percentages and upstream limited partners were not disclosed in the records reviewed. 2026 corporate announcement, 2021 transaction announcement
Ingredient sales, finished-product sales, patents and licensing create incentives for favorable positioning. Researchers also face publication incentives, and public institutions have policy and funding priorities. These are reasons to demand transparent methods and replication, not allegations of fraud.
Documented financial relationships
The linked relationships below distinguish ownership, grants, product supply and trial support. A modern ownership link does not establish control of a historical study.
Linked relationship list:
- BlackRock’s dated reported holding → Ingredion; this does not establish trial management or live holdings (2026 proxy and underlying-position dates).
- Corn Products, later Ingredion → acquired National Starch in 2010 (SEC-filed transaction; company timeline).
- National Starch product/packaging/logistics, Bayer cash and treatment supplies, and public/charitable grants → CAPP2 (original protocol finance). Other author relationships declared outside the submitted work remain separate (published disclosures).
- Ingredion named as supplier → 2024 controlled-feeding trial; payment terms remain unknown (original acknowledgment). Ingredion research funding and product gifts → separate 2018 STARCH trial (original disclosure).
- Manitoba commercialization grant → MSP; MSP research/publication support and company-linked authors/patents → Solnul and its same-cohort secondary report (government grant; trial disclosures; secondary-report disclosures).
- Gryphon backing → Metagenics; Metagenics research/product/design support and company-linked authors → 2022 blend study. Amway provided smart caps and acknowledged consultation (current backing announcement; original study disclosures). Exact supply-contract terms remain unknown.
- Edith Cowan partial funding and product trademark/patent application → 2026 IBS blend trial (original financial and IP statements).
- Wellcome grant → Indian rehydration trial; starch purchase versus donation remains unstated (original funding and methods). Shanghai Jahwa-affiliated coauthors and disclosed public grants → Rong Li’s separate constipation paper; affiliation is not proof of cash sponsorship (original affiliations and contributions).
The clinical work spans North America, Europe, Asia and Australia. Upstream owners of Nisshin Seifun and all nine Dutch-project commercial contributors, specific charity donor allocations, and supplier terms for the Thai blend were not fully traced; no clean independence claim rests on those gaps. Repeated use of the same commercial ingredients means geographic variety is not automatically independent replication. Manufacturer headquarters, crop origin, production plant and final retail packaging country are different facts; the specific manufacturing origin of every studied or retail lot was not established.
Regulatory status
The EU permits a narrowly framed claim about a smaller post-meal glucose rise when resistant starch replaces digestible starch. The condition is at least 14% resistant starch as a proportion of the food's total starch. This does not authorize saying that any resistant-starch supplement treats IBS, prevents diabetes or prevents cancer. It also does not describe adding a powder without the specified replacement. Regulation 432/2012, resistant starch entry
EFSA’s original opinion supported reduced post-meal glucose responses when RS replaces digestible starch, rather than simply adding RS while available carbohydrate stays unchanged. It judged the proposed broad digestive-health and normal-colon-metabolism wording insufficiently defined, which is not proof that RS has no possible digestive effect. A submitted dossier from National Starch Food Innovation is among its sources; regulatory authority does not make underlying experiments financially independent. This 2011 assessment is not a review of all later clinical trials (original assessment and source documentation).
The FDA's current Q&A lists high-amylose RS2 and cross-linked phosphorylated RS4 among fibers covered by enforcement discretion for dietary-fiber labeling while rulemaking is contemplated. That wording is narrower and more accurate than saying that every form is an FDA-approved treatment. A GRAS response for a specified ingredient and intended use is likewise not approval of all retail formulations or disease claims. FDA dietary-fiber Q&A, GRAS response
FAQs
Is cooled rice equivalent to a resistant starch supplement?
No. Food matrix, accompanying nutrients, processing and measured RS amount differ. EFSA defines several forms, and the wheat-food trial also differed in other components. A food or powder cannot inherit the other preparation’s clinical results merely because both contain RS (definitions; original mixed-food trial).
Is resistant starch the same as resistant maltodextrin?
No. The FDA lists resistant maltodextrin and the specified RS ingredients separately. Their labeling status and clinical trials should be assessed separately (current FDA fiber list).
Should I avoid heating every resistant starch product?
There is no universal instruction across RS1–RS5. Cooking and retrogradation change the laboratory digestibility of different preparations; that does not establish a single household treatment recipe. Follow actual product instructions and food-safety requirements (laboratory abstract; food-handling guidance).
Does more butyrate mean better gut health?
No clinical verdict follows from a stool measurement alone. Production and absorption affect the amount remaining in feces; the IBS blend changed microbial measures without improving its primary symptom outcome (original clinical results and SCFA discussion).
Does the cancer trial prove bananas prevent cancer?
No. CAPP2 tested a manufactured starch blend in people with Lynch syndrome; its primary colorectal result was null and the other Lynch-cancer signal was secondary. Neither replacing the tested intervention with bananas nor transferring the result to the general population is supported (original outcomes; original preparation protocol).
Why include studies that fail the independence standard?
To show what the headline claims actually rest on. Exclusion prevents those studies from determining the independent verdict; it does not erase their existence or establish that their results are false.
Is there a best type or dose?
This audit did not establish one for general gut health. A meaningful comparison would match the condition, measured resistant fraction, formulation and clinical outcome, then inspect both the study methods and financial relationships.
Sources and funding
The scorecard describes financial relationships identified in the records reviewed here. Tiers 1–4 mean, respectively, no relevant stake identified in those records, indirect ties, an interested party and direct commercial production/support; U means unresolved provenance. They are provisional editorial labels, not a complete funding-chain or ownership certificate. Credibility grades A–D separately describe accountability and source incentives; they are not clinical certainty grades. An interested corporate record may verify its own identity or transaction while remaining unsuitable as independent efficacy evidence.
| Source | Funder, owner or revenue model | Country or jurisdiction | Tier and credibility | Accuracy incentive and remaining gap |
|---|---|---|---|---|
| Luk-In 2024 | National Innovation Agency grant; no conflicts declared; commercial blend procurement unresolved | Thailand | U; C provisional | 87 completers; active mixed comparator; between-group null; registration posted after study |
| Rong Li 2026 | Public grants; two Shanghai Jahwa-affiliated coauthors; procurement unknown | China | 3 for corporate-author interest; U for procurement / B provisional | Uncontrolled human intervention; no complete corporate-author or supplier financial audit |
| Bush 2023 | MSP research/APC; employee, prior consultants, contracted CRO and sister-company patents | Canada | 4; C | Retrospectively registered; outlier exclusions, movement-level stool tests and safety dose-count conflict |
| NCT05242913 registry | MSP sponsor; government registry infrastructure | Canada trial / USA registry | 4; C for sponsor-submitted record | First posted 2022 after 2019–2020 study; no posted results; registry is not independent verification |
| Bush and Alfa 2024 | MSP funding; employee/consultant authors and related patents | Canada | 4; C | Same-cohort secondary analysis; mean symptom scores null, exploratory correlations |
| Iwata 2026 | Nisshin Seifun Group funding/food supply; six employee authors | Japan | 4; C | Primary bowel-frequency null; short mixed-food trial and unadjusted secondary/subgroup results |
| van den Belt 2025 | Dutch public-private project/nine companies; China Scholarship Council | Netherlands; cofunders USA/Europe/China | 4; C | Small RS arm, bacterial endpoint powering; clinical comparisons null; run-in within four weeks |
| Yan 2026 | Partial ECU funding and scholarships; ECU trademark/patent application | Australia / China | 4; C | Small per-protocol blend study; anxiety signal fails FDR, nominal/reported intake mismatch |
| Ramakrishna 2008 | Wellcome grant; National Starch product-payment terms unknown | India; UK funder; USA supplier | U; B provisional | Standard hospital care; assessor but not participant blinding; adjusted total-weight result null |
| Hanes 2022 | Metagenics fund/product/design/writing and linked authors; Amway smart caps | USA | 4; C | Mixed blend versus RS-rich comparator; adherence/dose associations do not isolate treatment |
| Huating Li 2024 | Public/university/EU/German support; Ingredion provided starches, payment terms unknown | China/Hong Kong SAR; Germany/EU; USA supplier | U; C provisional | Controlled-feeding crossover; short between-period result and weight regain during washout |
| Peterson 2018 STARCH | NIH plus Ingredion research funding and product gifts | USA | 4; C | Primary insulin sensitivity null; small secondary markers are not diabetes prevention |
| Mathers 2022 | Public/charitable and National Starch/Bayer support; additional outside-work author ties | UK-led international study | 4; C | Primary colorectal null; secondary Lynch-specific signal; not all participants followed 20 years |
| CAPP2 protocol | National Starch product/logistics; Bayer cash/treatments; public/charitable grants | UK-led international study | 4; C for design/support | 30 g ingredient equals 13.2 g RS; protocol records design, not independent outcome validation |
| SACN carbohydrate report | Government commission; 2015 register identifies outside commercial relationships | UK | 2 institutionally; B for definitions | Definition and older stool-bulking evidence; not full underlying-trial finance clearance |
| SACN 2015 annual report | PHE committee costs; disclosed personal/institutional Nestlé, Mars and other interests | UK | 2; A for disclosure record | Historical committee costs/register; not current personal-conflict certification |
| GAO FDA funding audit | US legislative-branch audit body | USA | 1 provisional; A for agency-finance record | Official online summary: FDA agency-wide fees do not identify an RS sponsor |
| RS5 laboratory abstract | University of Alabama internal programs reported | USA | 1 provisional; B for laboratory scope | Conference abstract only; full protocols/COI unavailable; no human clinical outcomes |
| FDA GRAS response | Regulator reviews Yale notifier’s submitted material | USA | 2 institutionally; A for response scope | Specified supervised rehydration use; no-questions letter, not general treatment approval |
| FDA fiber Q&A | Federal appropriations and agency-level user fees (GAO summary) | USA | 2 institutionally; A for labeling position | Enforcement discretion for listed fibers; no ingredient-specific sponsorship claim |
| NIDDK constipation guidance | US federal health institute | USA | 1 provisional; A for warning signs | General public guidance; not an RS trial or complete agency-budget audit |
| NIDDK gas guidance | US federal health institute | USA | 1 provisional; A for digestive context | General guidance; no RS-specific risk rate or universal safe supplement dose |
| FSA rice guidance | Government food-safety agency | UK | 1 provisional; A for food handling | Official cooling/storage precautions; not RS efficacy evidence |
| EU Regulation 432/2012 | Public regulatory process; official legal publication | European Union | 1 for legal text; A | Defined food-substitution claim; does not establish disease-treatment or financial independence |
| EFSA 2011 opinion | EU assessment of submitted evidence, including a National Starch dossier | Italy / EU | 1 institutionally; A for regulatory assessment | Substitution reasoning and nonspecific digestive wording; expert/included-study finance not fully traced |
| Wellcome financial announcement | Charity supported by a diversified investment portfolio | UK | 2; B for funding-model facts | Financial-reporting accountability; portfolio-to-historical-trial links not fully traced |
| SEC-filed National Starch acquisition release | Acquiring company's commercial self-disclosure | USA; seller Netherlands | 4; C for transaction facts | Securities disclosure accountability; promotional framing |
| Ingredion corporate timeline | Company revenue and shareholder capital | USA | 4; C for name/history facts | Checkable corporate history; no efficacy role |
| Ingredion 2026 proxy | Public company shareholder disclosure | USA | 4; C for dated holdings | Reporting duties; older underlying holdings and reporting changes |
| Manitoba grant announcement | Provincial government economic-development spending | Canada | 3 for promotion; A for grant amount | Public spending accountability; explicitly supports commercialization |
| Gryphon 2021 transaction announcement | Private-investment firm and portfolio-company interests | USA | 4; C for stated transaction | Named counterparties; forward-looking announcement and undisclosed terms |
| Gryphon/Metagenics 2026 announcement | Supplement sales, private capital and debt financing | USA | 4; C for current backing | Confirms continuing sponsor relationship; stake/limited-partner opacity |
This is a focused assessment of the sources discussed here, not a registered systematic review or proof that every RS study has been identified. Their clinical and financial limitations do not establish a universal supplement treatment. Every historical author relationship, private donor, supplier contract and investment holding has not been resolved. Unreported terms remain unknown rather than being treated as either clean or suspicious.
Primary studies, regulatory records and corporate filings are linked where used. No pooled estimate was calculated across unlike products, diseases and endpoints. Studies receiving company funding or donated materials, maker-linked studies and unresolved-procurement studies were not promoted into a definitive independent benefit claim.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
